ES2193136T3 - Variantes de inmunoglubina para receptores especificos de fc epsilon. - Google Patents

Variantes de inmunoglubina para receptores especificos de fc epsilon.

Info

Publication number
ES2193136T3
ES2193136T3 ES92918713T ES92918713T ES2193136T3 ES 2193136 T3 ES2193136 T3 ES 2193136T3 ES 92918713 T ES92918713 T ES 92918713T ES 92918713 T ES92918713 T ES 92918713T ES 2193136 T3 ES2193136 T3 ES 2193136T3
Authority
ES
Spain
Prior art keywords
ige
receptor
immunoglubine
epsilon
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92918713T
Other languages
English (en)
Inventor
Paula M Jardieu
Leonard G Presta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27114350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2193136(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2193136T3 publication Critical patent/ES2193136T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

SE DESCRIBEN DOS CLASES DE POLIPEPTIDOS DERIVADOS DE LA IGE HUMANA. UNA CLASE SE UNE SELECTIVAMENTE AL RECEPTOR DE LA IGE DE ALTA AFINIDAD SOBRE LAS CELULAS DE BASTON Y BASOFILOS, PERO NO AL RECEPTOR DE LA IGE DE BAJA AFINIDAD SOBRE LAS CELULAS B, MONOCITOS, EOSINOFILOS Y PLAQUETAS. LA OTRA CLASE SE UNE AL RECEPTOR DE BAJA AFINIDAD, PERO NO AL RECEPTOR DE ALTA AFINIDAD. LOS POLIPEPTIDOS DE UNION DIFERENCIAL DE ESTA INVENCION SON UTILES EN PROCEDIMIENTOS DE DIAGNOSTICO PARA RECEPTORES DE LA IGE O EN LA TERAPIA DE DESORDENES INTERMEDIADOS POR LA IGE TALES COMO LAS ALERGIAS. TAMBIEN SON UTILES EN LA PREPARACION DE ANTICUERPOS CAPACES DE UNIRSE A REGIONES DE LA IGE QUE PARTICIPAN EN LA UNION DEL RECEPTOR.
ES92918713T 1991-08-14 1992-08-14 Variantes de inmunoglubina para receptores especificos de fc epsilon. Expired - Lifetime ES2193136T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74476891A 1991-08-14 1991-08-14
US87949592A 1992-05-07 1992-05-07

Publications (1)

Publication Number Publication Date
ES2193136T3 true ES2193136T3 (es) 2003-11-01

Family

ID=27114350

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02009009T Expired - Lifetime ES2296839T3 (es) 1991-08-14 1992-08-14 Variantes de inmunoglobulinas para receptores fc-epsilon especificos.
ES92918713T Expired - Lifetime ES2193136T3 (es) 1991-08-14 1992-08-14 Variantes de inmunoglubina para receptores especificos de fc epsilon.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES02009009T Expired - Lifetime ES2296839T3 (es) 1991-08-14 1992-08-14 Variantes de inmunoglobulinas para receptores fc-epsilon especificos.

Country Status (12)

Country Link
EP (2) EP1260521B1 (es)
JP (1) JP3457962B2 (es)
AT (1) ATE233813T1 (es)
AU (2) AU2498192A (es)
CA (1) CA2113813C (es)
DE (3) DE69232944T2 (es)
DK (2) DK1260521T3 (es)
ES (2) ES2296839T3 (es)
HK (2) HK1014542A1 (es)
LU (1) LU91219I2 (es)
NL (1) NL300220I2 (es)
WO (1) WO1993004173A1 (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770396A (en) * 1992-04-16 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E
EP1452542A3 (en) * 1992-09-24 2007-05-02 Novartis AG Reshaped human monoclonal antibodies specific for IgE
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
GB9324013D0 (en) * 1993-11-22 1994-01-12 3I Res Expl Ltd Polypeptides
WO1995019181A1 (en) * 1994-01-18 1995-07-20 Genentech, Inc. A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS
US20040197326A1 (en) * 1995-07-27 2004-10-07 Genentech, Inc. Method for treatment of allergic asthma
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
TR199801722T2 (xx) * 1996-03-01 1998-12-21 Novartis Ag Peptit imm�nojenler.
US5958880A (en) * 1996-12-19 1999-09-28 Heska Corporation Feline Fc epsilon receptor alpha chain proteins and therapeutic uses thereof
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6057127A (en) 1998-01-29 2000-05-02 Heska Corporation Equine Fc epsilon receptor alpha chain nucleic acid molecules and uses thereof
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6504013B1 (en) * 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
WO2000050461A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
US6889145B1 (en) 2000-03-15 2005-05-03 Northwestern University Three-dimensional model of a Fc region of an IgE antibody and uses thereof
CA2423227C (en) 2000-10-12 2011-11-29 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6870034B2 (en) 2002-02-05 2005-03-22 Genentech, Inc. Protein purification
JP4319979B2 (ja) 2002-04-26 2009-08-26 ジェネンテック・インコーポレーテッド タンパク質の非アフィニティ精製
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
NZ563471A (en) 2002-11-08 2009-04-30 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
AU2003286003B2 (en) 2002-11-08 2011-05-26 Ablynx N.V. Stabilized single domain antibodies
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
KR101208291B1 (ko) 2003-04-04 2012-12-05 노파르티스 아게 고농도 항체 및 단백질 제형
HUE050171T2 (hu) 2003-07-28 2020-11-30 Genentech Inc Protein-A kioldódásának csökkentése protein-A affinitáskromatográfia során
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TWI391399B (zh) 2005-05-25 2013-04-01 Hoffmann La Roche 測定溶離多肽之鹽濃度之方法
US8080249B2 (en) 2005-06-30 2011-12-20 Risk Glifford G Methods to treating chronic obstructive pulmonary disease
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
WO2008091740A2 (en) 2007-01-22 2008-07-31 Genentech, Inc. Polyelectrolyte precipitation and purification of antibodies
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
EP2188302B1 (en) 2007-07-09 2017-11-01 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
PE20120259A1 (es) 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
EP2184608B1 (en) * 2007-08-23 2016-10-05 LSI Medience Corporation Non-specific reaction inhibitor
EP2840090B1 (en) 2007-10-30 2018-02-21 Genentech, Inc. Antibody purification by cation exchange chromatography
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
AU2008360625C1 (en) 2008-08-14 2017-01-19 Genentech, Inc. Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
EP2684570A1 (en) 2008-09-10 2014-01-15 F. Hoffmann-La Roche AG Compositions and methods for the prevention of oxidative degradation of proteins
US20110020327A1 (en) 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
SG171446A1 (en) 2008-12-16 2011-07-28 Millipore Corp Stirred tank reactor and method
SG173812A1 (en) 2009-02-27 2011-09-29 Genentech Inc Methods and compositions for protein labelling
PE20120359A1 (es) 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
CN104059955A (zh) 2009-08-11 2014-09-24 弗·哈夫曼-拉罗切有限公司 在无谷氨酰胺的细胞培养基中的蛋白质生产
RU2571929C2 (ru) 2009-09-01 2015-12-27 Дженентек, Инк. Улучшенная очистка белка посредством модифицированного элюирования белка а
KR102218495B1 (ko) 2010-03-22 2021-02-19 제넨테크, 인크. 단백질-함유 제제의 안정화에 유용한 조성물 및 방법
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
SG10201804385YA (en) 2010-05-17 2018-06-28 Emd Millipore Corp Stimulus responsive polymers for the purification of biomolecules
HUE030820T2 (en) 2010-05-28 2017-06-28 Hoffmann La Roche Decreasing Lactate Levels and Enhancing Polypeptide Production by Control of Lactate Dehydrogenase and Pyruvate Dehydrogenase Kinase Expression
WO2011163458A2 (en) 2010-06-24 2011-12-29 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
CN103154032A (zh) 2010-08-13 2013-06-12 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
ES2809211T3 (es) 2011-07-08 2021-03-03 Emd Millipore Corp Filtros de profundidad mejorados para procesos biotecnológicos desechables
EP2791169B1 (en) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
BR112014015101A8 (pt) 2011-12-22 2021-06-08 Genentech Inc métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos
CN104350156B (zh) 2012-03-27 2019-04-02 弗·哈夫曼-拉罗切有限公司 用于重组蛋白质的改进的收获操作
RU2711089C2 (ru) 2012-05-18 2020-01-15 Дженентек, Инк. Высококонцентрированные составы моноклональных антител
GB2503883A (en) * 2012-07-09 2014-01-15 King S College London Variant IgE with reduced affinity to CD23
EP2934602B1 (en) 2012-12-19 2019-02-27 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
KR102355306B1 (ko) 2014-07-09 2022-01-24 제넨테크, 인크. 세포 은행의 해동 회수를 개선하는 ph 조정
AU2017242031B2 (en) 2016-03-29 2023-07-27 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
KR102579836B1 (ko) 2016-12-22 2023-09-15 제넨테크, 인크. 동결건조된 폴리펩타이드의 재구성 시간을 감소시키기 위한 방법 및 제제
CA3049967A1 (en) * 2017-01-06 2018-07-12 The Regents Of The University Of California Therapeutic anti-ige antibodies and methods and compositions thereof
US20200199525A1 (en) 2017-06-08 2020-06-25 Polpharma Biologics S.A. Improved Methods of Cell Culture
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
BR112020006339A2 (pt) 2017-11-07 2020-11-03 Hubit Genomix, Inc. método para prevenção primária de distúrbios alérgicos durante a infância através de imunossupressão específica da classe ige
EA202092904A1 (ru) 2018-07-03 2021-04-22 Бристол-Маерс Сквибб Компани Способы получения рекомбинантных белков
US20210380923A1 (en) 2018-10-10 2021-12-09 Boehringer Ingelheim International Gmbh Method for membrane gas transfer in high density bioreactor culture
WO2020205716A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
EP3953380A4 (en) 2019-04-12 2023-01-25 Geltor, Inc. RECOMBINATION ELASTIN AND ASSOCIATED PRODUCTION
JP2022543781A (ja) 2019-08-01 2022-10-14 ブリストル－マイヤーズ スクイブ カンパニー フェッドバッチ細胞培養におけるタンパク質産生性の改良方法
EP4180454A1 (en) 2020-07-10 2023-05-17 Shanghai Jemincare Pharmaceuticals Co., Ltd. Anti-ige engineered antibody and application thereof
US20230357815A1 (en) 2020-09-22 2023-11-09 Bristol-Myers Squibb Company Methods for increasing productivity of therapeutic proteins
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
JPS63225397A (ja) * 1986-10-03 1988-09-20 Dainippon Pharmaceut Co Ltd 抗アレルギー作用を有する新規ペプチド
US4940782A (en) * 1987-06-08 1990-07-10 G. D. Searle & Co. Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore
GB8727045D0 (en) * 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
ATE121299T1 (de) * 1987-12-31 1995-05-15 Tanox Biosystems Inc Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden.

Also Published As

Publication number Publication date
DE69233716D1 (de) 2008-01-03
NL300220I2 (nl) 2006-08-01
DE69233716T2 (de) 2008-10-30
EP0602126A1 (en) 1994-06-22
JPH06509944A (ja) 1994-11-10
CA2113813A1 (en) 1993-03-04
HK1050696A1 (en) 2003-07-04
DK1260521T3 (da) 2008-03-25
EP1260521B1 (en) 2007-11-21
HK1014542A1 (en) 1999-09-30
AU7038096A (en) 1997-01-16
ES2296839T3 (es) 2008-05-01
DE122006000006I1 (de) 2006-04-27
NL300220I1 (nl) 2006-04-03
AU706584C (en) 2003-07-10
LU91219I2 (fr) 2006-04-03
JP3457962B2 (ja) 2003-10-20
DE122006000006I2 (de) 2011-06-16
DE69232944D1 (de) 2003-04-10
EP1260521A2 (en) 2002-11-27
WO1993004173A1 (en) 1993-03-04
DE69232944T2 (de) 2003-12-24
EP1260521A3 (en) 2004-01-02
AU2498192A (en) 1993-03-16
DK0602126T3 (da) 2003-06-16
AU706584B2 (en) 1999-06-17
ATE233813T1 (de) 2003-03-15
CA2113813C (en) 2005-04-12
EP0602126B1 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
ES2193136T3 (es) Variantes de inmunoglubina para receptores especificos de fc epsilon.
CA2345024A1 (en) Modified tgf-.beta. superfamily proteins
ES2150898T3 (es) Receptor humano fc(gamma)riii.
HK1112018A1 (en) Human toll-like receptor proteins, related reagents and methods
ES2187946T3 (es) Uso de interleucina-15.
ATE317852T1 (de) Pollen allergene
DE69714451D1 (de) Prionbindende proteine und deren verwendungen
ES2142317T3 (es) Polipeptidos de proteinas s y uso de los mismos.
AU666482B2 (en) Human herpesvirus type 6 protein p100, the corresponding DNA sequences, their preparation and use